Capstone Investment Advisors
IMNM icon

Capstone Investment Advisors’s Immunome IMNM Stock Holding History

Capstone Investment Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Sell
14,105
-551
-4% -$11.8K ﹤0.01% 1460
2026
Q1 		$321K Buy
+14,656
New +$326K ﹤0.01% 1347
2024
Q2 		– Sell
-42,300
Closed -$1.04M – 2261
2024
Q1 		$1.04M Buy
+42,300
New +$858K ﹤0.01% 1130

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Capstone Investment Advisors's IMNM Position: Q2 2026 in Review

Capstone Investment Advisors reduced its Immunome (IMNM) stake by 3.8% in Q2 2026, selling an estimated $11.8K and leaving 14,105 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #1460.

Capstone Investment Advisors first reported a position in IMNM in Q1 2024 and has held it in 3 quarters since. The position peaked at $1.04M in Q1 2024. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Capstone Investment Advisors held 14,105 shares of Immunome worth $299K as of Q2 2026.
  • Capstone Investment Advisors sold 551 Immunome shares in Q2 2026, an estimated $11.8K.
  • Immunome made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1460 holding.
  • Capstone Investment Advisors first reported a position in Immunome in Q1 2024 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Immunome position peaked at $1.04M in Q1 2024.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.